SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

MCET RSS Feed
Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: MyDogBuster, Dip66
Search This Board:
Last Post: 9/28/2016 12:31:22 AM - Followers: 536 - Board type: Free - Posts Today: 1

 
MultiCell Technologies, Inc. (MCET)

(U.S. Reporting: SEC Filer) 

Outstanding shares 5,000,948,700 as of Jul 8, 2015 

Office: (401) 762-0045  |  Email: info@multicelltech.com

http://www.MultiCellTech.com

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)


Partners

AmarinCorningPhizer

 

MultiCell inks R&D agreement with Oxis Biotech

MultiCell Technologies (OTCPK: MCET) subsidiary MultiCell Immunotherapeutics enters into a research and development and product license agreement with Oxis Biotech (OTCQB: OXIS) to create three novel antibody-drug conjugates (ADCs) based on Oxis' lead drug candidates and MultiCell's proprietary ADC platform technology. The ADCs will be targeted for the treatment of triple-negative breast cancer and multiple myeloma and associated osteolytic lesions.

Under the terms of the agreement, Oxis will pay MultiCell a license fee of $500K, up to $12.75M in clinical development milestones and a royalty of 3% on net sales. Oxis will also reimburse MultiCell up to $1.125M in development costs. MultiCell grants Oxis an option to purchase manufacturing rights to the three ADCs upon the payment of an additional $10M.

MultiCell retains all rights to its ADC platform for all indications and is free to pursue its own drug development programs and to partner with other firms.



Therapeutic Pipeline

MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development:

MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.
MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.
MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

 Therapeutic Candidate  

   Indication    

    Discovery Optimization    

    Preclinical Development    

    Phase 1    

    Phase 2/b   

    Phase 3    

 MCT-125 

PMSF

yes yes yes yes  

MCT-465

Cancer

yes yes      

MCT-475

Cancer

yes yes      

MCT-485

Cancer

yes yes      


Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.


MultiCell Technologies, Inc. Corporate Headquarters


68 Cumberland Street, Suite 301
Woonsocket, RI 02895


MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.


Find us on Google Maps      http://www.facebook.com/MCET.OB  
 


 Management and Board of Directors


Barbara (Corbett) Newmin - Investor Relations
Office: 941-637-9883



W. Gerald Newmin, Chairman and Chief Executive Officer
Office: 
817-292-7324


Dr. Steve Chang Ph. D., Director




Grant Miller, Director


Alan Tuchman, M.D.

Thomas A. Page, Director

Edward Sigmond, Director



 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MCET
Current Price
Volume:
Bid Ask Day's Range
SureTrader
MCET News: Current Report Filing (8-k) 09/26/2016 04:12:21 PM
PostSubject
#41636   Look at that today MCET is getting noticed. The dead cat bouncer 09/28/16 12:31:22 AM
#41635   Sounds conservative to me LOL ctvette2003 09/27/16 05:54:29 PM
#41634   $MCET MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical $Pistol Pete$ 09/27/16 05:19:33 PM
#41633   Don't forget their cure for AIDS. flu and simon wagstaff 09/27/16 04:48:21 PM
#41632   I think so as well. Cant wait computerguy101 09/27/16 04:01:11 PM
#41631   Something mega is lining up here. Dip66 09/27/16 03:42:02 PM
#41630   Awesome 8K! MCET >>> .0005+ primecomm 09/27/16 03:12:50 PM
#41629   Wow, Nice! MCT-125 has demonstrated efficacy in a PENNYMACHINE 09/27/16 03:11:33 PM
#41628   MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company TPX 09/27/16 03:07:58 PM
#41627   MCT-125 looks like it http://www.multicelltech.com/about-us/ PENNYMACHINE 09/27/16 03:06:50 PM
#41626   Lol! Please scroll down for the status simon wagstaff 09/27/16 03:05:39 PM
#41625   Coming next the phase 3 confirmation? It may TPX 09/27/16 03:05:06 PM
#41624   Its looks like their most effect drug at PENNYMACHINE 09/27/16 03:03:03 PM
#41623   MCIT/OXIS OVERVIEW TPX 09/27/16 02:51:33 PM
#41622   I agree PENNYMACHINE 09/27/16 02:44:43 PM
#41621   Yeah all that went way over my head! computerguy101 09/27/16 02:43:26 PM
#41620   Solid info. Dip66 09/27/16 02:37:51 PM
#41619   It's a college level presentation with zero achievements. simon wagstaff 09/27/16 02:37:40 PM
#41618   Thats *** AMAZING *** TPX 09/27/16 02:32:32 PM
#41617   looks like a breakdown of their drugs effect PENNYMACHINE 09/27/16 02:31:32 PM
#41616   MultiCell Immunotherapeutics, Inc. *** HUGE INFORMATION *** TPX 09/27/16 02:14:12 PM
#41615   MCET *** OTC Pink Limited Information Status *** http://www.otcmar TPX 09/27/16 02:07:17 PM
#41614   Got it to open via their Facebook page. simon wagstaff 09/27/16 11:31:37 AM
#41613   Impressed with what? simon wagstaff 09/27/16 11:18:14 AM
#41612   Impressed. Looking forward. Dip66 09/27/16 10:58:49 AM
#41611   Read the 8k. The dead cat bouncer 09/27/16 10:31:01 AM
#41610   Dead companies don't pay for news release 8k The dead cat bouncer 09/27/16 10:28:26 AM
#41609   Wow an 8k ctvette2003 09/27/16 09:21:41 AM
#41607   good. well they never took down one of The dead cat bouncer 09/23/16 06:29:51 PM
#41606   I would have to agree with Simon that Dip66 09/22/16 01:21:19 PM
#41605   I don't believe there is actually a "company" simon wagstaff 09/22/16 11:17:02 AM
#41604   I never wrote that employee thing but it The dead cat bouncer 09/22/16 10:28:14 AM
#41603   I never worked there. If I had they simon wagstaff 09/22/16 07:05:07 AM
#41602   i'm sure you were a good employee, but Dip66 09/21/16 08:42:44 PM
#41601   Bad employee? False accusations? A simple question. simon wagstaff 09/21/16 05:55:36 PM
#41600   Bad employees are not trustworthy. Would you leave The dead cat bouncer 09/21/16 03:22:01 PM
#41599   I was blocked immediately two years agfor asking simon wagstaff 09/21/16 02:59:35 PM
#41598   MultiCell does an amazing job deleting shareholder comments Dip66 09/21/16 12:40:21 PM
#41597   What a shame this turned into.. Barbara shouldn't Dip66 09/19/16 01:32:36 PM
#41595   It always amazed me how few shares he held. simon wagstaff 09/17/16 07:34:42 AM
#41594   My guess is Gerald received a nice fat Dip66 09/16/16 05:19:33 PM
#41593   My guess is they made their money long ago. simon wagstaff 09/16/16 12:36:06 PM
#41592   La Jolla can't be happy owning 10% of Dip66 09/16/16 11:30:05 AM
#41591   Company must be dumping stock.. Dip66 09/15/16 02:58:50 PM
#41590   I have never seen a company so vehemently simon wagstaff 09/14/16 07:32:19 AM
#41589   This company has left shareholders with nothing and Dip66 09/13/16 08:01:21 PM
#41588   That's cool we talk on here so much The dead cat bouncer 09/13/16 12:59:44 PM
#41587   Thanks but I am out of this POS, ctvette2003 09/13/16 10:32:28 AM
#41586   Barbara Newmin: 941-637-9883 Dip66 09/13/16 10:30:36 AM
#41585   You missed it. 6 mo ago I went ctvette2003 09/10/16 06:19:21 PM
PostSubject